Connect public, paid and private patent data with Google Patents Public Datasets

Test composition and method for the in vitro determination of thyroid function

Download PDF

Info

Publication number
US3716632A
US3716632A US3716632DA US3716632A US 3716632 A US3716632 A US 3716632A US 3716632D A US3716632D A US 3716632DA US 3716632 A US3716632 A US 3716632A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
indicator
ph
blue
test
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
M Fader
J Christner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/804Radioisotope, e.g. radioimmunoassay
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/826Additives, e.g. buffers, diluents, preservatives

Abstract

The thyroid hormone content of blood serum can be readily determined by using an in vitro radioactive thyroid function test system containing a ''''protein error'''' pH indicator such as bromcresol purple. Such a ''''protein error'''' indicator provides color and detects the presence of the test sample, inhibits the formation of free iodide and decreases the adsorption of radioactive tagged thyroid substance to the walls of the container enclosing same.

Description

Fade et I 51 Feb. 13,1973

[54] TEST COMPOSITION AND METHOD FOR THE IN VTTRO DETERMINATION OF THYROID FUNCTION [75] Inventors: Marshall Lloyd Fader; James Edward Christner, both of Elkhart, Ind.

[73] Assignee: Miles Laboratories, Inc., Elkhart, I11.

[22] Filed: April 27, 1970 [211 App]. No.: 32,396

[52] U.S. Cl. ..424/1, 23/230 B, 252/30l.1 R [51] int. Cl. ..A6lk 27/04 [58] Field of Search ..424/l 2, 7; 252/30l.1;

[56] References Cited UNITED STATES PATENTS 12/1969 Keston ..23/230 B 4/1970 Murty et al. ..424/] X 6/1970 Murty et al. ..424/l X Primary ExaminerBenjamin R. Padgett Attorney-Joseph C. Schwalbach, Michael A. Kondzella, Louis E. Davidson and Harry T. Stephenson [57] ABSTRACT 16 Claims, No Drawings TEST COMPOSITION AND METHOD FOR THE IN VITRO DETERMINATION OF TI'IYROID FUNCTION BACKGROUND OF THE INVENTION Numerous tests have recently been developed to determine thyroid function in vitro without exposure of the patient to ionizing radiation. For example, specific plasma proteins known as thyroxine-binding proteins or TBP are the primary binding sites for the hormones produced by the thyroid gland. Since the TBF have a strong affinity for thyroid hormone, they will bind any free thyroid hormone available until they become saturated. In this test, such hormone is made available to the TB? in a sample of the-patients serum and a secondary binding site consisting of a resin powder or crosslinked dextran (Sephadex) is provided to take up any of the added radioactive triiodothyronine or thyroxine (hereinafter referred to as T or T respectively) not bound by the TBP. Thus, the test provides an estimation of the saturation level of the TB? in a given serum sample which is an indirect but reliable indication of thyroid function. A large resin uptake indicates hyperthyroidism whereas a small resin uptake indicates hypothyroidism.

Two such tests for thyroid function are described in US. Pat. Nos. 3,206,602 and 3,451,777. Since no color change is involved in either test, the operator can become confused if the procedural steps are interrupted. In addition, the decomposition of radioactive iodinated T to the free iodide form, combined with considerable adsorption of the aqueous buffered radioactive T solution to glass or plastic containers, produces a significant error in the determination of the thyroid hormone content of the serum sample.

SUMMARY OF THE INVENTION The main object of the present invention is to provide a thyroid function test solution containing a pH indicator which possesses the three fold advantage of (1) providing a color change when the serum sample is added thereto (2) inhibiting the formation of free iodide from radioactive iodinated T and (3) decreasing the adsorption of radioactive iodinated T to the walls of the vessel containing the same.

DESCRIPTION OF THE PREFERRED EMBODIMENTS Although thyroid function tests may be performed in many different ways, one common method involves adding an appropriate amount ofa buffered aqueous solu tion of radioactive triiodothyronine or thyroxine and serum to a column of ion exchange resin such as Amberlite IRA 400 made by Rohm and Haas Co. of Philadelphia, Pa. or a cross linked dextran such as Sephadex G-25 made by Pharmacia Corp. of Uppsala, Sweden. The column is then drained and the radioactivity measured in a gamma ray counting instrument for 1 minute. The column is thereafter eluted with distilled water and the radioactivity remaining on the column is again measured for 1 minute. The percent retention is then calculated by comparing the two readings. Retentions of 41 percent to 6l percent are considered normal with cross-linked dextran (Sephadex) columns and 25 percent to 35 percent with resin columns.

It has now been found that by adding a protein error" pH indicator to an aqueous radioactive T solution prior to combining with the serum sample or by adding same to the combined T solution and serum sample, one can achieve a highly improved test system.

The pH indicator employed in the present invention is of the protein error type which changes color in the presence of albumin without a significant actual change in pH. When such an indicator is added in a concentration of about 5. to micrograms per milliliter of aqueous I -T reagent buffered at a pH of 5 the reagent changes from its initial color to a second color when the serum is added. This second color acts as a marker which will appear at varying heights on the resin or dextrancolumndepending on the last operation step completed in the test procedure, since the color will move with the solvent front.

A preferred indicator is bromcresol purple which changes color from yellow to purple within the pH range of 5.2 to 6.8. When mixed with aqueous radioactive T solution, the yellow-orange color will turn to a grey-green color when serum is added at a ratio of 0.05 milliliter of serum to 0.45 milliliter of reagent mixture. Thus, the green color indicates the presence of the serum. Other satisfactory indicators which can be employed depending on the pH of the buffer system are (I) chlorphenol red, which changes from red to violet at a pH of 6.5 (2) tetrabromphenol blue, which changes from yellow to blue at a pH of 3.0 (3)bromphenol blue, which changes from yellow to purple at a pH of 3.0 (4) bromcresol green, which changes color from yellow to blue at a pH of 3.0 and (5) bromthymol blue, which changes from green to yellow at a pH of 6.5. In practice, the colors of the color change are not important as long as a difference can be easily seen.

Preferably, the improved T test reagent with pH indicator of this invention will contain the following:

l triiodothyronine Triiodothyronine unlabelled Bromcresol purple Distilled water q.s. to

4.0 micrograms 26.0 micrograms 0.18 grams 3.0 liters In addition to the color change which occurs in the use of a pH indicator of the type disclosed, another advantage resides in the unforeseen property of the indicator to inhibit the formation of free iodide from the I -T employed in the T reagent. This is important, since the gamma counters cannot distinguish between I -T and free I and all of the dose I is counted initially during the test procedure. Washing with water removes any free I from the column, since only the hormonal materials remain thereon. Thus, if the percent of free iodide is above 5 percent of the total dose counts, the T ratio is subject to a significant error of from 5 percent to 10 percent.

In a series of tests, a buffered aqueous solution of T containing 60 micrograms of bromcresol purple per milliliter prepared as shown in the foregoing example was stored under various conditions in a polyethylene container and the percent of free iodide formed was compared with a similar solution containing no pH indicator. The initial solutions employed contained about 2 percent free iodide. After 90 days at room temperature, the radioactive T solution containing the indicator showed 2.25 percent free iodide compared to 5.2 percent free iodide in the control sample containing no indicator. After 60 days at 40 C., the T test solution with pH indicator contained 4.25 percent free iodide, whereas the control sample had a free iodide content of 9.0 percent.

A still further advantage of the use of a pH indicator in T test solution is to inhibit the adsorption of radioactive T to the walls of a plastic or glass container. Propylene glycol and albumin have been used in the past to reduce such adsorption but these additives interfere with the thyroid function test. In actual tests, aqueous radioactive T solutions containing one of several indicators at a concentration of 60 micrograms per milliliter of solution were rotated on a wheel in a polyethylene container for 14 days and the percent activity remaining was compared with a control sample containing no indicator. The results obtained showed that over 90 percent of the radioactivity (after correction for physical decay) remained in those solutions containing bromthymol blue, chlorphenol red, bromcresol purple and tetrabromphenol blue, whereas with solutions containing phenol red or bromcresol green, 80 percent of the radioactivity remained, while those containing bromphenol blue retained 70 percent of the radioactivity in solution. Under the same test conditions, the control sample not containing one of the mentioned indicators retained only 32% of the radioactivity in solution. Similar results are obtained with glass containers.

Decreased adsorption oflike magnitude has been observed when plastic or glass containers are prewashed prior to filling with radioactive -T;, reagent devoid of indicator. The term prewashed" means contacting (such as by rinsing, soaking or flushing) the interior surfaces of said containers with an aqueous, buffered solution of one of the pH indicators hereinbefore disclosed. Bromcresol purple or bromthymol blue are the preferred indicators. These are employed at a concentration of from 50 to 70 micrograms per milliliter of water buffered to a pH of about 5.

It is to be understood that the T employed in the test compositions of this invention can be made radioactive with either F or 1", although l is preferred, since it has a half-life of 56 days compared to 1"" which has a half-life of 8 days.

What is claimed is:

1. In a test composition for determining thyroid function comprising a radioactive thyroid hormone and a buffer for establishing the pH of thecomposition in a predetermined range, the improvement which comprises adding to the composition a color responsive is used to maintain the pH of the composition at about 5 3. A test composition as in claim 1 wherein the indicator is selected from the group consistin of bromcresol purple, chlorphenol red, tetrabromp enol blue,

bromphenol blue, bromcresol green and bromthymol blue.

4. A test composition as in claim 1 wherein the indicator is bromcresol purple.

5. A test composition as in claim 1 wherein the indicator is bromthymol blue.

6. A test composition as in claim 1 wherein the indicator is present in a concentration of about 60 micrograms per milliliter of composition.

7. A test composition as in claim 1 wherein the thyroid substance is triiodothyronine.

8. In a method for determining thyroid function wherein blood serum is added to a composition comprising a radioactive tagged thyroid hormone and a buffer for establishing the pH of the composition in a predetermined range, the improvement which comprises the addition of a color responsive amount of a protein error type pH indicator which changes color in response to protein at the pH of the buffer prior to the addition of the serum.

9. A method as in claim 8 wherein the indicator is selected from the group consisting of bromcresol purple, chlorphenol red, tetrabromphenol blue, bromphenol blue, bromcresol green and bromthymol blue.

10. A method as in claim 8 wherein the indicator is bromcresol purple.

11. A method as in claim 8 wherein the indicator is present in a concentration of about 60 micrograms per milliliter of composition.

12. A method as in claim 8 wherein the thyroid substance is triiodothyronine.

13. A method of inhibiting the adsorption of radioactive triiodothyronine from an aqueous solution thereof on the walls of a polyethylene container which comprises adding to said aqueous solution an adsorption inhibiting amount of a protein error type pH indicator.

M. A method as in claim 13 wherein the indicator is selected from the group consisting of bromcresol purple, chlorphenol red, tetrabromphenol blue, bromphenol blue, bromcresol green and bromthymol blue.

15. A method as in claim 13 wherein the indicator is bromthymol blue.

16. A method as in claim 13 wherein the container is prewashed with an aqueous solution of bromcresol purple at a concentration of from 50 to micrograms per milliliter of water.

Claims (15)

1. In a test composition for determining thyroid function comprising a radioactive thyroid hormone and a buffer for establishing the pH of the composition in a predetermined range, the improvement which comprises adding to the composition a color responsive amount of a protein error type pH indicator which changes color in response to protein at the pH of the said buffer.
2. A test composition as in claim 1 wherein the buffer is used to maintain the pH of the composition at about 5.
3. A test composition as in claim 1 wherein the indicator is selected from the group consisting of bromcresol purple, chlorphenol red, tetrabromphenol blue, bromphenol blue, bromcresol green and bromthymol blue.
4. A test composition as in claim 1 wherein the indicator is bromcresol purple.
5. A test composition as in claim 1 wherein the indicator is bromthymol blue.
6. A test composition as in claim 1 wherein the indicator is present in a concentration of about 60 micrograms per milliliter of composition.
7. A test composition as in claim 1 wherein the thyroid substance is triiodothyronine.
8. In a method for determining thyroid function wherein blood serum is Added to a composition comprising a radioactive tagged thyroid hormone and a buffer for establishing the pH of the composition in a predetermined range, the improvement which comprises the addition of a color responsive amount of a protein error type pH indicator which changes color in response to protein at the pH of the buffer prior to the addition of the serum.
9. A method as in claim 8 wherein the indicator is selected from the group consisting of bromcresol purple, chlorphenol red, tetrabromphenol blue, bromphenol blue, bromcresol green and bromthymol blue.
10. A method as in claim 8 wherein the indicator is bromcresol purple.
11. A method as in claim 8 wherein the indicator is present in a concentration of about 60 micrograms per milliliter of composition.
12. A method as in claim 8 wherein the thyroid substance is triiodothyronine.
13. A method of inhibiting the adsorption of radioactive triiodothyronine from an aqueous solution thereof on the walls of a polyethylene container which comprises adding to said aqueous solution an adsorption inhibiting amount of a protein error type pH indicator.
14. A method as in claim 13 wherein the indicator is selected from the group consisting of bromcresol purple, chlorphenol red, tetrabromphenol blue, bromphenol blue, bromcresol green and bromthymol blue.
15. A method as in claim 13 wherein the indicator is bromthymol blue.
US3716632A 1970-04-27 1970-04-27 Test composition and method for the in vitro determination of thyroid function Expired - Lifetime US3716632A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US3239670 true 1970-04-27 1970-04-27

Publications (1)

Publication Number Publication Date
US3716632A true US3716632A (en) 1973-02-13

Family

ID=21864745

Family Applications (1)

Application Number Title Priority Date Filing Date
US3716632A Expired - Lifetime US3716632A (en) 1970-04-27 1970-04-27 Test composition and method for the in vitro determination of thyroid function

Country Status (5)

Country Link
US (1) US3716632A (en)
CA (1) CA956097A (en)
DE (1) DE2120442C3 (en)
FR (1) FR2090714A5 (en)
GB (1) GB1347498A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960492A (en) * 1974-05-31 1976-06-01 Nuclear Diagnostics, Inc. Method for determining an index of binding protein content of blood
US3985867A (en) * 1974-01-02 1976-10-12 The Radiochemical Centre Limited Immunoassays employing a colored second antibody
US4108974A (en) * 1976-08-27 1978-08-22 Bio-Rad Laboratories, Inc. Radioimmunoassay for thyroid hormone
US4278653A (en) * 1979-02-01 1981-07-14 New England Nuclear Corporation Methods and kits for double antibody immunoassay providing a colored pellet for easy visualization
US4299812A (en) * 1978-11-29 1981-11-10 Diagnostic Products Corp. Immunoassay of thyroxine in neonates using dried blood samples
US4311690A (en) * 1978-06-20 1982-01-19 Damon Corporation Test set and method for the determination of free hormones

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3485587A (en) * 1956-02-29 1969-12-23 Miles Lab Protein indicator
US3507618A (en) * 1964-11-27 1970-04-21 Squibb & Sons Inc Apparatus and method for determining thyroid function
US3516794A (en) * 1964-12-14 1970-06-23 Squibb & Sons Inc Apparatus and method for determining thyroid function

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3485587A (en) * 1956-02-29 1969-12-23 Miles Lab Protein indicator
US3507618A (en) * 1964-11-27 1970-04-21 Squibb & Sons Inc Apparatus and method for determining thyroid function
US3516794A (en) * 1964-12-14 1970-06-23 Squibb & Sons Inc Apparatus and method for determining thyroid function

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985867A (en) * 1974-01-02 1976-10-12 The Radiochemical Centre Limited Immunoassays employing a colored second antibody
US3960492A (en) * 1974-05-31 1976-06-01 Nuclear Diagnostics, Inc. Method for determining an index of binding protein content of blood
US4108974A (en) * 1976-08-27 1978-08-22 Bio-Rad Laboratories, Inc. Radioimmunoassay for thyroid hormone
US4311690A (en) * 1978-06-20 1982-01-19 Damon Corporation Test set and method for the determination of free hormones
US4299812A (en) * 1978-11-29 1981-11-10 Diagnostic Products Corp. Immunoassay of thyroxine in neonates using dried blood samples
US4278653A (en) * 1979-02-01 1981-07-14 New England Nuclear Corporation Methods and kits for double antibody immunoassay providing a colored pellet for easy visualization

Also Published As

Publication number Publication date Type
CA956097A1 (en) grant
DE2120442B2 (en) 1973-05-10 application
CA956097A (en) 1974-10-15 grant
DE2120442C3 (en) 1973-11-29 grant
FR2090714A5 (en) 1972-01-14 application
DE2120442A1 (en) 1971-11-11 application
GB1347498A (en) 1974-02-27 application

Similar Documents

Publication Publication Date Title
Rigler Radiobiological analysis of inorganic phosphorus in lakewater: With 2 figures and 1 table in the text
Nauman et al. Total and free triiodothyronine in human serum
Pearlman et al. Steroid-protein interaction with particular reference to testosterone binding by human serum
Wolff et al. Thyroxine displacement from serum proteins and depression of serum protein-bound iodine by certain drugs
Helmkamp et al. High specific activity iodination of γ-globulin with iodine-131 monochloride
STERLING et al. Resin uptake of I131-triiodothyronine as a test of thyroid function
Katz Iron and protein kinetics studied by means of doubly labeled human crystalline transferrin
Fahey et al. Chromatography of serum proteins in normal and pathologic sera: The distribution of protein-bound carbohydrate and cholesterol, siderophilin, thyroxin-binding protein, B 12-binding protein, alkaline and acid phosphatases, radioiodinated albumin and myeloma proteins
Benson Jr et al. Accelerated chromatographic analysis of amino acids in physiological fluids containing glutamine and asparagine
Meyer et al. The binding of aldosterone to plasma proteins in normal, pregnant, and steroid-treated women
Deshpande et al. Accumulation of tritiated oestradiol by human breast tissue
Longsworth Diffusion measurements, at 25, of aqueous solutions of amino acids, peptides and sugars
Berson et al. Quantitative aspects of the reaction between insulin and insulin-binding antibody
GENUTH et al. A radioimmunological assay method for insulin using insulin-125I and gel filtration
Crispell et al. Studies of plasma volume using human serum albumin tagged with radioactive iodine 131
Pippin et al. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates
McFarlane THE BEHAVIOR OF I131‐LABELED PLASMA PROTEINS IN VIVO
Blin et al. Isolation of large molecular weight DNA from agarose gels forfurther digestion by restriction enzymes
Takeda et al. Fibrinogen metabolism and distribution in patients with the nephrotic syndrome
US3615223A (en) Cement retarder determination
Cooper et al. Labeling human erythrocytes with radiochromium
Pressman et al. The zone of localization of antibodies: V. An attempt to saturate antibody-binding sites in mouse kidney
Giri et al. Some Factors Influencing Quantitative Determination of Amino Acids Separated by Circular Paper Chromatography
US4366143A (en) Assay for the free portion of substances in biological fluids
Wish et al. Direct determinations of plasma, cell, and organ-blood volumes in normal and hypervolemic mice